Opinion|Videos|October 15, 2024
Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring
Panelists discuss how they approach luspatercept dosing strategies in clinical practice; manage treatment-related adverse events such as fatigue, hypertension, and diarrhea; and monitor labs for signs of relapse, while also considering real-world dose escalation outcomes and the correlation between peripheral blood and bone marrow biopsy mutations in patients with MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is your dosing strategy for luspatercept in your clinical practice?
- Please comment on Patel K, et al. Real-world luspatercept dose escalation and outcomes. EHA 2024 abstract.
- Please describe some potential treatment-related adverse events associated with luspatercept that you’ve observed in your clinical practice.
- How do you manage fatigue, hypertension, and diarrhea?
- What labs do you monitor and recheck for if you are concerned that this patient is relapsing?
- Resource links: DeZern AE, et al. Correlation between PB and BMBx mutations from national MDS study. ASH 2023 abstract.
Advertisement
Related to this article
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.
Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.
Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
3
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
4
QTX3034 Plus Cetuximab Receives FDA Fast Track Designation in KRAS G12D–Mutated CRC
5